Merck KGaA (OTCMKTS:MKGAY) Given Average Rating of “Buy” by Analysts

Shares of Merck KGaA (OTCMKTS:MKGAY – Get Rating) have received a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $252.50.

MKGAY has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their price target on Merck KGaA from €270.00 ($290.32) to €250.00 ($268.82) and set an “overweight” rating on the stock in a research report on Monday, March 14th. UBS Group upgraded Merck KGaA from a “sell” rating to a “neutral” rating in a research report on Monday, February 28th.

MKGAY remained flat at $$38.36 during trading hours on Monday. Merck KGaA has a 52 week low of $32.53 and a 52 week high of $42.02. The business’s 50 day simple moving average is $38.36 and its two-hundred day simple moving average is $38.36.

Merck KGaA Company Profile (Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

See Also